The study compares the perceived treatment burden in patients undergoing intravitreal anti-VEGF treatment for either wet age related macular degeneration, macular edema after retinal vein occlusions or diabetic macular edema. This study is the first to the investigator's knowledge to compare treatment burden between all three patient groups, which also differ in age and socioeconomic circumstances. The results are of interest to all ophthalmologists who prescribe anti-VEGF treatments, as they show factors which can influence patient adherence und thus the efficacy of said therapies.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Severitiy of subjective treatment burden due to intravitreal anti-VEGF therapy assessed by questionnaire
Timeframe: From May 2023 to April 2024